Clinical Trials

29 enrolled

Breast Neoplasms

NCT01612871 2026-04-14

MIRHO

39 enrolled

Breast Neoplasms

NCT00893061 2026-03-17

MNEMOSYNE

44 enrolled

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

263 enrolled

Breast Neoplasms

NCT00066690 2026-02-06

SOFT

3,066 enrolled 15 charts

Breast Neoplasms

NCT00066703 2026-02-06

TEXT

2,672 enrolled 14 charts

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

1,017 enrolled

Breast Neoplasms

NCT03280563 2025-11-10

MORPHEUS HR+BC

Phase 1/2 Completed

144 enrolled 25 charts

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT02007512 2025-09-02

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

247 enrolled 27 charts

Breast Neoplasms

NCT03300557 2025-08-29

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

40 enrolled 13 charts

Gynecologic

Endometrial Hyperplasia, Endometrial Neoplasms

NCT04300790 2025-07-29

METALLICA

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02123823 2025-07-15

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

164 enrolled 21 charts

Tumor-Agnostic

Neoplasms

NCT00253422 2025-06-04

SoFEA

698 enrolled 19 charts

Breast Neoplasms

NCT03554044 2025-05-21

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

20 enrolled

Breast Neoplasms

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Breast Neoplasms

NCT03219476 2025-04-29

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

37 enrolled 10 charts

Breast Neoplasms

NCT00265759 2025-04-23

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

622 enrolled 18 charts

Breast Neoplasms

NCT03659136 2025-02-24

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

103 enrolled 16 charts

Breast Neoplasms

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT01870505 2024-12-09

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

52 enrolled 19 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT03355157 2024-10-01

PADMA

130 enrolled

Breast Neoplasms, Patient Acceptance of Health Care

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Breast Neoplasms

NCT02188745 2024-07-17

POLLY

19 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT02676986 2024-07-05

ARB

221 enrolled

Primary Breast Cancer ER+ve

NCT01594216 2024-06-12

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

25 enrolled 8 charts

Estrogen-receptor Positive Invasive Metastatic Breast Cancer

NCT04129216 2024-05-07

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

30 enrolled 10 charts

Breast Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT02648477 2024-03-19

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

30 enrolled 11 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT03312738 2024-01-23

BOLERO-5

159 enrolled 25 charts

Breast Neoplasms

NCT02258451 2023-11-24

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

283 enrolled 22 charts

Breast Neoplasms

NCT04465097 2023-10-17

NeoTEE

30 enrolled

Breast Neoplasms

NCT00066573 2023-08-25

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

7,576 enrolled 10 charts

Breast Neoplasms

NCT00083174 2023-08-25

ExCel

4,560 enrolled 16 charts

Breast Neoplasms

NCT02028364 2023-08-24

PEARL

55 enrolled

Breast Neoplasms

NCT02598557 2023-08-22

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

180 enrolled 46 charts

Breast Carcinoma In Situ, Breast Neoplasms

NCT03555877 2023-07-07

AMICA

56 enrolled

Breast Cancer Metastatic

NCT02666105 2023-05-31

Exemestane in Post-Menopausal Women With NSCLC

6 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01698918 2023-05-03

BOLERO-4

202 enrolled 19 charts

Breast Neoplasms

NCT00432172 2023-04-03

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

189 enrolled 17 charts

Breast Neoplasms

NCT02894398 2023-03-13

INGE-B

388 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT00128843 2023-03-06

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

103 enrolled

Breast Neoplasms

NCT02049957 2023-02-08

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

118 enrolled 30 charts

Breast Neoplasms

NCT02440230 2022-12-30

SEAT

110 enrolled

Breast Neoplasms

NCT03948568 2022-09-30

REaCT-RETT

262 enrolled

Breast Neoplasms

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Phase 1/2 Completed

41 enrolled 12 charts

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT01989780 2022-08-04

BOOSTER

160 enrolled

Breast Neoplasms

NCT02623751 2022-06-21

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

15 enrolled